Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

7.610 +0.050 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mind Medicine Mindmed Inc

< Previous 1 2 3 4 5 Next >
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Participate in Upcoming Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Mind Medicine Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
From Mind Medicine Inc.
Via Business Wire
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
From Mind Medicine Inc.
Via Business Wire
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
From Mind Medicine Inc.
Via Business Wire
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Mind Medicine Inc.
Via Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine
Via Business Wire
MindMed to Participate in June Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed to Participate at May Investor Conferences
From MindMed
Via Business Wire
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Reports First Quarter 2024 Financial Results and Business Updates
From MindMed
Via Business Wire
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
From MindMed
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
From MindMed
Via Business Wire
MindMed to Present at Upcoming May Medical Conferences
From MindMed
Via Business Wire
MindMed to Present at Upcoming April Medical Conferences
From Mind Medicine
Via Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
From MindMed
Via Business Wire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
From MindMed
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
From MindMed
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.